Journal of International Oncology ›› 2021, Vol. 48 ›› Issue (1): 11-17.doi: 10.3760/cma.j.cn371439-20201126-00002
Previous Articles Next Articles
Received:2020-11-26
Revised:2020-12-08
Online:2021-01-08
Published:2021-01-21
"
| 肿瘤类型 | 化疗方案 | 建议 | |
|---|---|---|---|
| 小细胞肺癌 | ①CDE方案(环磷酰胺+多柔比星+依托泊苷) | ||
| ②拓扑替康 | |||
| ③ICE方案(异环磷酰胺+卡铂+依托泊苷) | |||
| 非小细胞肺癌 | DC方案(多西他赛+卡铂) | ||
| 肿瘤类型 | 化疗方案 | 建议 | |
| 结直肠癌 | FOLFOXIRI方案(氟尿嘧啶+亚叶酸钙+奥沙利铂+伊立替康) | ||
| 食管癌和胃癌 | DCF方案(多西他赛+顺铂+氟尿嘧啶) | ||
| 胰腺癌 | FOLFIRINOX方案(奥沙利铂+亚叶酸+伊立替康+氟尿嘧啶) | ||
| 卵巢癌 | ①托泊替康 | ||
| ②紫杉醇 | |||
| ③多西他赛 | |||
| 头颈部肿瘤 | TPF方案(多西他赛+顺铂+氟尿嘧啶) | ||
| 乳腺癌 | ①TCH方案(多西他赛+卡铂+曲妥珠单抗) | ||
| ②ddAC-2wP方案(剂量密集多柔比星+环磷酰胺+序贯紫杉醇双周) | |||
| ③ddAC-2wP方案(剂量密集多柔比星+环磷酰胺+序贯紫杉醇单周) | |||
| ④TAC方案(多西他赛+多柔比星+环磷酰胺) | |||
| ⑤TE方案(多西他赛+表柔比星) | |||
| ⑥TC方案(多西他赛+环磷酰胺) | |||
| ⑦FEC方案(氟尿嘧啶+表柔比星+环磷酰胺) | |||
| ⑧高剂量多西他赛+噻替哌+卡铂联合 | |||
| ⑨高剂量多西他赛+噻替哌联合 | |||
| 肾癌 | 多柔比星+吉西他滨 | ||
| 睾丸癌 | ①VeIP方案(长春碱+异环磷酰胺+顺铂) | ||
| ②VIP方案(依托泊苷+异环磷酰胺+顺铂) | |||
| ③TIP方案(紫杉醇+异环磷酰胺+顺铂) | 建议预防性应用 | ||
| 膀胱癌 | 剂量密集的MVAC(甲氨蝶呤+长春碱+多柔比星+顺铂) | PEG-rhG-CSF | |
| 霍奇金淋巴瘤 | ①BEACOPP方案(博来霉素+依托泊苷+多柔比星+环磷酰胺+长春新碱+丙卡巴肼+泼尼松) | ||
| ②Brentuximabvedotin(维汀-布仑妥昔单抗)+AVD方案(多柔比星+长春碱+达卡巴嗪) | |||
| 非霍奇金淋巴瘤 | ①ICE方案(异环磷酰胺+卡铂+依托泊苷) | ||
| ②剂量调整的EPOCH方案(依托泊苷+泼尼松+长春新碱+环磷酰胺+多柔比星) | |||
| ③剂量密集的CHOP方案(环磷酰胺+多柔比星+长春新碱+泼尼松)±利妥昔单抗 | |||
| ④MINE方案(美司钠+异环磷酰胺、米托蒽醌+足叶乙甙) | |||
| ⑤DHAP方案(地塞米松+顺铂+阿糖胞苷) | |||
| ⑥ESHAP方案(依托泊苷+甲泼尼龙+顺铂+阿糖胞苷) | |||
| ⑦高剂量HyperCVAD方案(环磷酰胺+长春新碱+多柔比星+地塞米松)±利妥昔单抗 | |||
| 黑色素瘤 | ①以达卡巴嗪为主的联合方案(达卡巴嗪+顺铂+长春碱) | ||
| ②以达卡巴嗪为主联合IL-2、干扰素α的方案(达卡巴嗪+顺铂+长春碱+IL-2+干扰素α) | |||
| 骨肉瘤 | ①高剂量异环磷酰胺联合高剂量甲氨蝶呤 | ||
| ②多柔比星和顺铂(新辅助) | |||
| ③甲氨蝶呤、多柔比星和顺铂(初诊为高级别) | |||
| ④甲氨蝶呤、多柔比星和顺铂联合异环磷酰胺、依托泊苷(初诊为高级别) | |||
| ⑤顺铂动脉介入联合多柔比星静脉滴注 | |||
| ⑥顺铂动脉介入联合多柔比星、异环磷酰胺静脉滴注 | |||
| 软组织肉瘤 | ①MAID方案(美司钠+多柔比星+异环磷酰胺+达卡巴嗪) | ||
| ②标准剂量多柔比星或高剂量表柔比星 | |||
| ③异环磷酰胺和多柔比星 | |||
| 多发性骨髓瘤 | ①DT-PACE方案(地塞米松+沙利度胺+顺铂+多柔比星+环磷酰胺+依托泊苷) | ||
| ②VTD-PACE方案(DT-PACE方案+硼替佐米) | |||
"
| 肿瘤类型 | 化疗方案 | 风险因素评估 | 建议 |
|---|---|---|---|
| 小细胞肺癌 | ①CAV方案(环磷酰胺+多柔比星+长春新碱) | ①年龄>65岁并接受足剂量 强度化疗 ②既往接受过化疗或放疗 ③治疗前已经存在中性粒 细胞减少 ④肿瘤疾病累及骨髓 ⑤近期外科手术和/或开放性 创伤 ⑥肝功能障碍(胆红素> 20 mg/L) ⑦肾功能障碍(肌酐清除率< 50 mg/min) ⑧既往发生过FN ⑨恶性血液淋巴系统疾病 ⑩女性患者(小细胞肺癌) ⑪心血管疾病(非霍奇金淋巴瘤) | 若患者出现≥1项风险因素时,需要考虑给予预防性应用PEG-rhG-CSF |
| ②依托泊苷+顺铂/卡铂 | |||
| 非小细胞肺癌 | ①TP方案(紫杉醇+顺铂) | ||
| ②NP方案(顺铂+长春瑞滨) | |||
| ③DP方案(顺铂+多西他赛) | |||
| ④顺铂 | |||
| ⑤依托泊苷 | |||
| ⑥CP方案(卡铂+紫杉醇) | |||
| ⑦多西他赛 | |||
| 结直肠癌 | FOLFOX方案(氟尿嘧啶+亚叶酸钙+奥沙利铂) | ||
| 食管癌和胃癌 | ①伊立替康、顺铂 | ||
| ②表柔比星、顺铂、氟尿嘧啶 | |||
| ③表柔比星、顺铂、卡培他滨 | |||
| 胰腺癌 | FOLFIRINOX方案(奥沙利铂+亚叶酸+伊立替康+氟尿嘧啶) | ||
| 卵巢癌 | 卡铂和多西他赛 | ||
| 宫颈癌 | ①顺铂和托泊替康 | ||
| ②紫杉醇和顺铂 | |||
| ③托泊替康 | |||
| ④伊立替康 | |||
| 子宫肉瘤 | 多西他赛 | ||
| 乳腺癌 | ①含多西他赛的方案±曲妥珠单抗 | ||
| ②CMF方案(环磷酰胺+甲氨蝶呤+氟尿嘧啶) | |||
| ③AC-T方案(多柔比星+环磷酰胺序贯多西他赛,仅多西他赛治疗周期) | |||
| ④AC-TH方案(多西他赛序贯给药+曲妥珠单抗) | |||
| ⑤FEC-T方案(氟尿嘧啶+表柔比星+环磷酰胺序贯多西他赛) | |||
| ⑥紫杉醇21 d方案 | |||
| ⑦ddEC-T方案(剂量密集表柔比星+环磷酰胺序贯紫杉醇) | |||
| ⑧E-CMF方案(表柔比星序贯环磷酰胺+甲氨蝶呤+氟尿嘧啶) | |||
| ⑨XT方案(卡培他滨+多西他赛标准方案) | |||
| 睾丸癌 | ①依托泊苷和顺铂 | ||
| ②BEP方案(博来霉素+依托泊苷+顺铂) | |||
| 前列腺癌 | 卡巴他赛 | ||
| 非霍奇金淋巴瘤 | ①GDP方案(吉西他滨+地塞米松+顺铂)±利妥昔单抗 | ||
| ②CHOP方案(环磷酰胺+多柔比星+长春新碱+泼尼松)±利妥昔单抗,包括含聚乙二醇脂质体多柔比星替代多柔比星的治疗方案 | |||
| ③CHP方案(环磷酰胺+多柔比星+泼尼松)+本妥昔单抗 | |||
| ④苯达莫司汀 |
| [1] |
Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group[J]. JAMA, 1999,281(17):1623-1627. DOI: 10.1001/jama.281.17.1623.
doi: 10.1001/jama.281.17.1623 pmid: 10235156 |
| [2] |
Takada M, Fukuoka M, Kawahara M, et al. Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104[J]. J Clin Oncol, 2002,20(14):3054-3060. DOI: 10.1200/JCO.2002.12.071.
doi: 10.1200/JCO.2002.12.071 pmid: 12118018 |
| [3] |
Donadieu J, Fenneteau O, Beaupain B, et al. Congenital neutropenia: diagnosis, molecular bases and patient management[J]. Orphanet J Rare Dis, 2011,6:26. DOI: 10.1186/1750-1172-6-26.
doi: 10.1186/1750-1172-6-26 pmid: 21595885 |
| [4] | Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2016,27:111-118. DOI: 10.1093/annonc/mdw325. |
| [5] |
Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients[J]. Cancer, 2006,106(10):2258-2266. DOI: 10.1002/cncr.21847.
doi: 10.1002/cncr.21847 pmid: 16575919 |
| [6] |
Becker PS, Griffiths EA, Alwan LM, et al. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020[J]. JNCCN, 2020,18(1):12-22. DOI: 10.6004/jnccn.2020.0002.
doi: 10.6004/jnccn.2020.0002 pmid: 31910384 |
| [7] | 中国抗癌协会肿瘤临床化疗专业委员会, 中国抗癌协会肿瘤支持治疗专业委员会. 肿瘤化疗导致的中性粒细胞减少诊治专家共识[J]. 中国肿瘤临床, 2019,46(17):876-882. DOI: 10.3969/j.issn.1000-8179.2019.17.913. |
| [8] |
O'Rourke N, Roqué I, Figuls M, et al. Concurrent chemoradiotherapy in non-small cell lung cancer[J]. Cochrane Database Syst Rev, 2010(6): CD002140. DOI: 10.1002/14651858.CD002140.pub3.
doi: 10.1002/14651858.CD010696.pub2 pmid: 27327415 |
| [9] |
Mac Manus M, Lamborn K, Khan W, et al. Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and deve-lopment of a predictive model[J]. Blood, 1997,89(7):2303-2310. DOI: 10.1007/s002770050284.
pmid: 9116273 |
| [10] |
Sekine I, Sumi M, Ito Y, et al. Phase Ⅰ study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage Ⅲ non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2012,82(2):953-959. DOI: 10.1016/j.ijrobp.2011.01.008.
pmid: 21377282 |
| [11] |
Christodoulou M, Blackhall F, Mistry H, et al. Compliance and outcome of elderly patients treated in the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial[J]. J Thorac Oncol, 2019,14(1):63-71. DOI: 10.1016/j.jtho.2018.09.027.
pmid: 30391573 |
| [12] |
Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the eso-phagus (NEOCRTEC5010): a phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018,36(27):2796-2803. DOI: 10.1200/JCO.2018.79.1483.
doi: 10.1200/JCO.2018.79.1483 pmid: 30089078 |
| [13] |
Tang HR, Ma HF, An SM, et al. A phase Ⅱ study of concurrent chemoradiotherapy with paclitaxel and cisplatin for inoperable eso-phageal squamous cell carcinoma[J]. Am J Clin Oncol, 2016,39(4):350-354. DOI: 10.1097/COC.0000000000000069.
pmid: 24732811 |
| [14] |
Videtic GM, Fung K, Tomiak AT, et al. Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limi-ted small cell lung cancer decreases survival and disease control[J]. Lung Cancer, 2001,33(2-3):249-258. DOI: 10.1016/s0169-5002(00)00240-3.
doi: 10.1016/s0169-5002(00)00240-3 pmid: 11551420 |
| [15] |
Ohira M, Kubo N, Yamashita Y, et al. Impact of chemoradiation-induced myelosuppression on prognosis of patients with locally advanced esophageal cancer after chemoradiotherapy followed by eso-phagectomy[J]. Anticancer Res, 2015,35(9):4889-4895. DOI: 10.1097/COC.0b013e31805c1410.
pmid: 26254384 |
| [16] |
Xu C, Yang SP, Zhang Y, et al. Neutropenia during the first cycle of induction chemotherapy is prognostic for poor survival in locoregionally advanced nasopharyngeal carcinoma: a real-world study in an endemic area[J]. Cancer Res Treat, 2018,50(3):777-790. DOI: 10.4143/crt.2017.255.
doi: 10.4143/crt.2017.255 pmid: 28745036 |
| [17] |
Bunn PA Jr, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase Ⅲ randomized study of the Southwest Oncology Group[J]. J Clin Oncol, 1995,13(7):1632-1641. DOI: 10.1200/JCO.1995.13.7.1632.
doi: 10.1200/JCO.1995.13.7.1632 pmid: 7602352 |
| [18] |
Sheikh H, Colaco R, Lorigan P, et al. Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase Ⅱ trial[J]. Lung Cancer, 2011,74(1):75-79. DOI: 10.1016/j.lungcan.2011.01.020.
doi: 10.1016/j.lungcan.2011.01.020 |
| [19] | Gomes F, Finn CF, Gutierrez FF, et al. Use of G-CSF and prophylactic antibiotics with concurrent chemoradiotherapy in limited-stage small cell lung cancer: results from the phase Ⅲ CONVERT trial[J]. Ann Oncol, 2017,28(2):61-62. DOI: 10.1093/annonc/mdx195. |
| [20] | Radiation Emergency Medical Management. Myeloid cytokines for treatment of acute exposure to myelosuppressive doses of radiation: hematopoietic subsyndrome of acute radiation syndrome (H-ARS)[R/OL]. 2015 [2020-11-25]. https://www.remm.nlm.gov/cytokines.htm. |
| [21] |
中国临床肿瘤学会, 中国抗淋巴瘤联盟, 中国抗癌协会乳腺癌专业委员, 等. 聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)临床应用中国专家共识[J]. 中国肿瘤临床, 2016,43(7):271-274. DOI: 10.3969/j.issn.1000-8179.2016.07.239.
doi: doi:10.3969/j.issn. 1000- 8179.2016.07.239 |
| [22] | 中国临床肿瘤学会指南工作委员会. 肿瘤放化疗相关中性粒细胞减少症规范化管理指南[J]. 中华肿瘤杂志, 2017,39(11):868-878. DOI: 10.3760/cma.j.issn.0253-3766.2017.11.011. |
| [23] |
Liu F, Du Y, Cai B, et al. A clinical study of polyethylene glycol recombinant human granulocyte colony-stimulating factor prevention neutropenia syndrome in patients with esophageal carcinoma and lung cancer after concurrent chemoradiotherapy[J]. J Cancer Res Ther, 2017,13(5):790-795. DOI: 10.4103/jcrt.JCRT_320_17.
pmid: 29237905 |
| [24] | 刘芳, 俞伟, 梁岚清, 等. 聚乙二醇重组人粒细胞集落刺激因子预防头颈部肿瘤同步放化疗后中性粒细胞减少症的研究[J]. 中国临床保健杂志, 2015,18(4):386-389. DOI: 10.3969/J.issn.1672-6790.2015.04.018. |
| [25] |
Shi YK, Chen Q, Zhu YZ, et al. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study[J]. Anticancer Drugs, 2013,24(6):641-647. DOI: 10.1097/CAD.0b013e3283610b5d.
doi: 10.1097/CAD.0b013e3283610b5d pmid: 23571496 |
| [26] |
杨晟, 何小慧, 刘鹏, 等. 聚乙二醇化重组人粒细胞集落刺激因子预防化疗后中性细粒细胞减少的有效性分析[J]. 中国肿瘤临床, 2015,42(12):626-631. DOI: 10.3969/j.issn.1000-8179.20150577.
doi: doi:10.3969/j.issn. 1000- 8179.20150577 |
| [27] |
Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of re-commendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline[J]. J Clin Oncol, 2006,24(19):3187-3205. DOI: 10.1200/JCO.2006.06.4451.
doi: 10.1200/JCO.2006.06.4451 pmid: 16682719 |
| [28] |
Wu FP, Wang J, Wang H, et al. Clinical observation of the therapeutic effects of pegylated recombinant human granulocyte colony-stimulating factor in patients with concurrent chemoradiotherapy-induced grade Ⅳ neutropenia[J]. Exp Ther Med, 2015,9(3):761-765. DOI: 10.3892/etm.2014.2160.
doi: 10.3892/etm.2014.2160 pmid: 25667625 |
| [29] | 刘青, 关嵩, 曹峰, 等. PEG-rhG-CSF对同步放化疗中性粒细胞缺乏挽救性治疗临床分析[J]. 中华肿瘤防治杂志, 2017,24(7):481-485. |
| [30] |
Pfeil AM, Allcott K, Pettengell R, et al. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for pro-phylaxis of chemotherapy-induced neutropenia in patients with can-cer: a systematic review[J]. Support Care Cancer, 2015,23(2):525-545. DOI: 10.1007/s00520-014-2457-z.
pmid: 25284721 |
| [31] |
Kirshner JJ, Heckler CE, Janelsins MC, et al. Prevention of pegfilgrastim-induced bone pain: a phase Ⅲ double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base[J]. J Clin Oncol, 2012,30(16):1974-1979. DOI: 10.1200/JCO.2011.37.8364.
pmid: 22508813 |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
